NEW YORK (GenomeWeb) – OncoCyte announced today it has reached definitive agreements with certain investors for the purchase of units to raise approximately $3.6 million in gross proceeds.

The investors include members of OncoCyte's management and its board, as well as new institutional investors, the company said. Net proceeds from the offering will be used for working capital, including further development of the company's confirmatory lung cancer diagnostic test called DetermaVu, and other general corporate purposes.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

An analysis of UK Biobank data finds hemochromatosis to be more prevalent than thought, according to the BBC.

An analysis finds that female biomedical researchers receive fewer prizes than male ones, and when they do win prizes, they are less prestigious.

Federal researchers tell the Los Angeles Times that the shutdown is causing missed research opportunities as they try to keep their experiments going.

In Nature this week: improved genomic analysis using a graph genome reference, tumor mutational burden could predict clinical response to immune checkpoint inhibitors, and more.